Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2026-08-06 16:13:19 ET · period of report 2026-08-04 · accession 0001439222-26-000120 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-06 16:13 | 2026-08-04 | AGIO | Gheuens Sarah | Chief Medical Off | S - Sale | $30.48 | -30.0K | 54.6K | -35% | -$914.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2026-08-04 | S | D | 30,000 | $30.48 | 54,645 | D | — | — | (F1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. (F2) The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |